The Biotech and Genomics fund invests primarily (at least 80%) in biotechnology, genomics, and medical research companies worldwide, focusing on those expected to offer strong returns, with a bias toward U.S.-based firms. The fund manager selects investments based on financial health, management quality, and growth potential, while actively managing the portfolio with reference to the NASDAQ Biotechnology Total Return Index (GBP) as a performance benchmark. This index reflects NASDAQ-listed biotech stocks, providing a basis for investors to compare the Fund’s performance.